SCHEMBL6987201

SCHEMBL6987201

Cc1cc2cccnc2c2c1C(=O)C(C(=O)O)C=N2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.40
CCR8 P51685 2/20 0.40
CCR5 P51681 1/20 0.34
PSMD14 O00487 1/20 0.34
COPS5 Q92905 1/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
PDE4A P27815 3/20 0.33
TRPM5 Q9NZQ8 1/20 0.33
SSTR1 P30872 1/20 0.33
SSTR4 P31391 1/20 0.33
COMT P21964 1/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967454 0.86 L3MBTL1 (0.39) NPC1RAB9AL3MBTL1COMTALDH1A1
SCHEMBL6975182 0.85 L3MBTL1 (0.40) CCR1CCR8L3MBTL1CASP3SENP8
SCHEMBL965521 0.85 SLC40A1 (0.40) NPC1RAB9AL3MBTL1PDE4ATRPM5
SCHEMBL1509799 0.80 SLC40A1 (0.37) NPC1RAB9AL3MBTL1CASP3PDE4A
SCHEMBL1509598 0.77 LMNA (0.43) CCR1CCR8CCR5L3MBTL1ALDH1A1
SCHEMBL6985131 0.75 KDM4E (0.37) NPC1RAB9AL3MBTL1ALDH1A1LMNA
SCHEMBL6984797 0.74 MAPK1 (0.38) CCR1CCR8NPC1RAB9AL3MBTL1
SCHEMBL6985519 0.74 RELA (0.38) NPC1RAB9AL3MBTL1PDE4AALDH1A1
SCHEMBL5819956 0.69 DAO (0.36) NPC1RAB9AL3MBTL1LMNAMAPT
SCHEMBL6981101 0.68 L3MBTL1 (0.43) CCR1CCR8NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US claimed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 CCR1 245/4885CCR8 1610/4885CCR5 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.